Double maintains 2 strategies that include SYRE - Spyre Therapeutics, Inc.
Yahoo
Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD") and other immune-mediated diseases, today announced its first quarter 2025 financial results and provided program and corporate updates.
Finnhub
WALTHAM, Mass. — WALTHAM, Mass. — Spyre Therapeutics, Inc. on Thursday reported a loss of $44.8 million in its first quarter. On a per-share basis, the Waltham, Massachusetts-based company...
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced two poster presentations at Digestive Disease Week (DDW) 2025, being held May 3-6, 2025, in San Diego, California.
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 64,400 shares of common stock of Spyre to seven n
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that it has initiated dosing in a healthy volunteer, Phase 1 clinical trial of its investigational half-life extended anti-IL-23 monoclonal antibody, SPY003. This milestone marks our
SeekingAlpha
Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -39.69% | $140.49M | 0.59% |
BTAL | -39.63% | $361.41M | 1.43% |
VIXY | -38.72% | $109.64M | 0.85% |
IVOL | -19.37% | $353.94M | 1.02% |
FTSD | -15.48% | $212.46M | 0.25% |
FXY | -13.09% | $838.61M | 0.4% |
SPTS | -12.74% | $5.76B | 0.03% |
SCHO | -9.57% | $10.87B | 0.03% |
VGSH | -9.46% | $22.38B | 0.03% |
TBLL | -9.33% | $2.46B | 0.08% |
XONE | -9.30% | $603.24M | 0.03% |
BILS | -8.31% | $3.96B | 0.1356% |
ULST | -7.88% | $637.77M | 0.2% |
CARY | -7.57% | $347.36M | 0.8% |
TPMN | -7.33% | $31.54M | 0.65% |
STPZ | -7.33% | $446.46M | 0.2% |
CGSM | -7.31% | $658.61M | 0.25% |
UTWO | -7.08% | $387.71M | 0.15% |
SHYM | -7.06% | $322.93M | 0.35% |
IBTI | -6.70% | $995.39M | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 65.09% | $4.85B | 0.35% |
IBB | 60.05% | $5.22B | 0.45% |
GNOM | 59.50% | $40.65M | 0.5% |
ARKG | 58.38% | $944.78M | 0.75% |
PBE | 57.36% | $214.12M | 0.58% |
CPRJ | 56.57% | $48.43M | 0.69% |
IWC | 56.28% | $766.88M | 0.6% |
IWO | 54.97% | $11.36B | 0.24% |
VTWO | 54.05% | $12.07B | 0.07% |
IWM | 54.04% | $63.95B | 0.19% |
SCHA | 53.86% | $16.91B | 0.04% |
QQA | 53.41% | $225.66M | 0.29% |
PTH | 53.33% | $96.56M | 0.6% |
XPH | 53.33% | $136.58M | 0.35% |
ISCG | 53.25% | $645.00M | 0.06% |
KJUL | 53.25% | $113.35M | 0.79% |
BBH | 53.03% | $327.42M | 0.35% |
ESML | 52.98% | $1.81B | 0.17% |
NUSC | 52.93% | $1.14B | 0.31% |
KOMP | 52.90% | $2.20B | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBIL | 0.35% | $782.40M | 0.15% |
DFNM | 0.51% | $1.53B | 0.17% |
FLMI | 0.53% | $649.76M | 0.3% |
STIP | 0.58% | $11.88B | 0.03% |
BSV | -0.59% | $38.35B | 0.03% |
IBD | 0.61% | $380.12M | 0.43% |
BAB | 0.61% | $919.66M | 0.28% |
BWX | -0.61% | $1.41B | 0.35% |
AGZD | -0.63% | $127.42M | 0.23% |
SMB | 0.73% | $269.10M | 0.07% |
BNDX | 0.74% | $64.67B | 0.07% |
KCCA | -0.80% | $97.18M | 0.87% |
CANE | -1.15% | $10.71M | 0.29% |
WEAT | 1.17% | $115.83M | 0.28% |
GOVT | 1.22% | $27.25B | 0.05% |
CLIP | 1.26% | $1.50B | 0.07% |
GVI | 1.30% | $3.37B | 0.2% |
SUB | 1.31% | $9.40B | 0.07% |
FTSM | -1.31% | $6.54B | 0.45% |
UTEN | -1.37% | $192.72M | 0.15% |
Current Value
$14.581 Year Return
Current Value
$14.581 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BEAM | 57.58% | $1.73B | -27.49% | 0.00% |
APGE | 53.40% | $2.42B | -24.39% | 0.00% |
ACLX | 53.07% | $3.22B | +10.72% | 0.00% |
IMNM | 52.49% | $696.10M | -44.44% | 0.00% |
IDYA | 51.76% | $1.52B | -58.32% | 0.00% |
XNCR | 51.55% | $583.60M | -63.49% | 0.00% |
KYMR | 51.42% | $1.95B | -15.67% | 0.00% |
SYNA | 50.69% | $2.52B | -29.56% | 0.00% |
RGNX | 50.39% | $433.39M | -46.03% | 0.00% |
CRSP | 49.81% | $3.14B | -34.78% | 0.00% |
DIOD | 49.40% | $2.25B | -33.06% | 0.00% |
OVID | 49.17% | $21.71M | -90.68% | 0.00% |
RCKT | 48.80% | $724.54M | -71.26% | 0.00% |
VSH | 48.70% | $2.05B | -36.62% | 2.67% |
KRYS | 48.67% | $3.77B | -20.42% | 0.00% |
BHVN | 48.60% | $1.62B | -58.86% | 0.00% |
BLFS | 48.54% | $1.05B | +0.09% | 0.00% |
CRNX | 48.06% | $2.92B | -39.88% | 0.00% |
DNLI | 47.64% | $2.06B | -30.04% | 0.00% |
IPGP | 47.25% | $2.78B | -26.19% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HMST | 0.01% | $242.19M | +25.98% | 0.00% |
PEP | 0.10% | $180.30B | -28.19% | 4.14% |
HSY | 0.13% | $33.16B | -21.37% | 3.44% |
KR | -0.14% | $44.68B | +24.17% | 1.89% |
MNOV | 0.20% | $68.17M | -2.80% | 0.00% |
TH | 0.35% | $690.70M | -39.27% | 0.00% |
GIS | 0.38% | $29.79B | -23.81% | 4.42% |
CNK | 0.40% | $3.67B | +78.94% | 0.25% |
CORT | 0.56% | $7.78B | +166.38% | 0.00% |
UUU | -0.67% | $4.93M | +40.20% | 0.00% |
DG | 0.69% | $20.45B | -36.56% | 2.55% |
FATBB | 0.74% | $50.77M | -11.65% | 9.83% |
NOC | 0.80% | $67.51B | -0.35% | 1.76% |
PG | 0.95% | $380.78B | -3.25% | 2.51% |
SRRK | -0.99% | $2.92B | +115.29% | 0.00% |
CLX | 1.03% | $16.64B | -1.45% | 3.61% |
AMT | -1.20% | $99.10B | +8.59% | 3.09% |
K | -1.26% | $28.49B | +32.17% | 2.77% |
MCK | -1.36% | $88.42B | +27.17% | 0.39% |
DUK | 1.38% | $90.12B | +12.74% | 3.61% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -13.93% | $22.95B | +20.67% | 1.12% |
CL | -9.98% | $72.64B | -5.18% | 2.25% |
VHC | -9.92% | $34.69M | +74.89% | 0.00% |
BTCT | -8.86% | $25.35M | +93.08% | 0.00% |
STG | -8.58% | $27.05M | -37.35% | 0.00% |
FMTO | -8.39% | $45.74M | -99.96% | 0.00% |
ED | -8.16% | $36.75B | +5.26% | 3.28% |
CME | -6.98% | $98.74B | +28.80% | 3.84% |
KMB | -5.59% | $45.57B | +1.99% | 3.58% |
LITB | -5.45% | $21.28M | -72.45% | 0.00% |
VZ | -5.26% | $183.32B | +8.02% | 6.21% |
PULM | -4.23% | $23.82M | +239.64% | 0.00% |
T | -4.16% | $196.66B | +57.98% | 4.07% |
COR | -3.94% | $55.43B | +28.90% | 0.56% |
MO | -3.81% | $97.80B | +26.35% | 6.94% |
NEUE | -3.31% | $62.05M | +13.56% | 0.00% |
HRL | -2.89% | $16.59B | -16.43% | 3.81% |
KDP | -2.86% | $45.55B | -1.76% | 2.70% |
EXC | -2.81% | $43.84B | +12.45% | 3.59% |
KO | -2.66% | $308.23B | +13.09% | 2.75% |